Efficacy and Safety of Eyebon Eye Wash Solution in Allergic Conjunctivitis after Conjunctival Cedar Pollen Allergen Challenge

Not Applicable

• Conditions: allergic conjunctivitis

• Registration Number: JPRN-UMIN000021320
• Lead Sponsor: Tsurumi University

Brief Summary

The 199th Annual Meeting of the Japanese Ophthalmological Society (2015)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-03-11
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

Not provided

Exclusion Criteria

1. have had a history of allergic hypersensitivity or known hypersensitivity to any compound or excipient of the Eyebon Eye Wash 2. have had the presence of any ocular condition that could affect the patient's safety or study parameters (narrow angle glaucoma requiring medication or laser treatment, clinically significant blepharitis, follicular conjunctivitis, iritis, pterygium, or a diagnosis of dry eye). 3. have had a known history of vernal keratoconjunctivitis and/or atopic eratoconjunctivitis; 4. have had an ocular surgical intervention within 3 months prior to study and/or a history of refractive surgery within 6 months prior to study. 5. have had any presence of active ocular infection (bacterial, viral, or fungal) or preauricular lymphadenopathy, or positive history of an ocular herpetic infection at their visits. 6. have had any uncontrolled systemic disease. 7. have had a history of status asthmaticus, a known history of persistent moderate or severe asthma, or a known history of moderate to severe allergic asthmatic reactions to study allergens. 8. have manifested signs or symptoms of clinically active allergic conjunctivitis (defined as the presence of any itching or >1 hyperemia in the conjunctival vessel bed) in either eye at the start visit. 9. be a female who was currently pregnant, nursing, or planning a pregnancy. 10. have used any of the disallowed medications (topical, topical ophthalmic, systemic and/or injectable) during the period indicated before and during the study period, including *aspirin, aspirin containing products *H1-antagonist antihistamines (including ocular) and all other anti-allergy therapies including prescription, over-the-counter, homeopathy agents *all other topical ophthalmic preparations (including tear substitutes) other than study drops *corticosteroids or mast cell stabilizers *depot corticosteroids

Study & Design

• Study Type: Interventional
• Study Design: Not specified